References
- 1. WHO. Diabetes Fact sheet N°312. 2015 January 2015 [cited; Available from: http://www.who.int/mediacentre/factsheets/fs312/en/
- 2. ARIAS LF. The Kidney in Diabetes Mellitus and other Metabolic Disorders. [cited 2015 2015 02 26]; Available from: http://www.kidneypathology.com/English_version/Diabetes_and_others.html
- 3. WHO. Global status report on noncommunicable diseases 2010. World Health Organization. 2011.
- 4. R. ALPERN, M. CAPLAN, O. MOE. Seldin and Giebisch's The Kidney; Physiology & Pathophysiology. Academic Press; 2012. p. 2605-23.
- 5. ALNEMRI ES, LIVINGSTON DJ, NICHOLSON DW, SALVESEN G, THORNBERRY NA, WONG WW, et al. Human ICE/CED-3 protease nomenclature. Cell. 1996; 87(2): 171.
- 6. FIORETTO P, STEFFES MW, BROWN DM, MAUER SM. An overview of renal pathology in insulin-dependent diabetes mellitus in relationship to altered glomerular hemodynamics. Am J Kidney Dis. 1992; 20(6): 549-58.
- 7. COVIC A., COVIC M., SEGALL L., GUSBETH-TATOMIR P. Manual de Nefrologie. Polirom; 2007.
- 8. GOLDIN A, BECKMAN JA, SCHMIDT AM, CREAGER MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006; 114(6): 597-605.
- 9. ZHANG C, LIAO Y, Li Q, CHEN M, ZHAO Q, DENG R, et al. Recombinant adiponectin ameliorates liver ischemia reperfusion injury via activating the AMPK/eNOS pathway. PLoS One. 2013; 8(6): e66382.
- 10. FUJII Y, OKADA A, YASUI T, NIIMI K, HAMAMOTO S, HIROSE M, et al. Effect of adiponectin on kidney crystal formation in metabolic syndrome model mice via inhibition of inflammation and apoptosis. PLoS One. 2013; 8(4): e61343.
- 11. DING M, CARRAO AC, WAGNER RJ, XIE Y, JIN Y, RZUCIDLO EM, et al. Vascular smooth muscle cell-derived adiponectin: a paracrine regulator of contractile phenotype. J Mol Cell Cardiol. 2012; 52(2): 474-84.
- 12. QATANANI M, LAZAR MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev. 2007; 21(12): 1443-55.
- 13. WOLF G, ZIYADEH FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int. 1999; 56(2): 393-405.
- 14. RIGALLEAU V, GARCIA M, LASSEUR C, LAURENT F, MONTAUDON M, RAFFAITIN C, et al. Large kidneys predict poor renal outcome in subjects with diabetes and chronic kidney disease. BMC Nephrol. 2010; 11: 3.
- 15. PENESCU M, MANDACHE E. The value of kidney biopsy in diabetes mellitus. Rom J Morphol Embryol. 2010; 51(1): 13-9.
- 16. DALLA VESTRA M, SALLER A, MAUER M, FIORETTO P. Role of mesangial expansion in the pathogenesis of diabetic nephropathy. J Nephrol. 2001; 14 Suppl 4: S51-7.
- 17. SUSZTAK K, RAFF AC, SCHIFFER M, BOTTINGER EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 2006; 55(1): 225-33.
- 18. ZHANG Y, SHI Y, LIU Y, DONG H, LIU M, LI Y, et al. Growth pattern switch of renal cells and expression of cell cycle related proteins at the early stage of diabetic nephropathy. Biochem Biophys Res Commun. 2007; 363(1): 159-64.
- 19. WOLF G. Cell cycle regulation in diabetic nephropathy. Kidney Int Suppl. 2000; 77: S59-66.
- 20. HARPER JW, ADAMI GR, WEI N, KEYOMARSI K, ELLEDGE SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993; 75(4): 805-16.
- 21. ALMOND JB, COHEN GM. The proteasome: a novel target for cancer chemotherapy. Leukemia. 2002; 16(4): 433-43.
- 22. GERVAIS JL, SETH P, ZHANG H. Cleavage of CDK inhibitor p21(Cip1/Waf1) by caspases is an early event during DNA damage-induced apoptosis. J Biol Chem. 1998; 273(30): 19207-12.
- 23. WOLF G, SCHROEDER R, ZIYADEH FN, THAISS F, ZAHNER G, STAHL RA. High glucose stimulates expression of p27Kip1 in cultured mouse mesangial cells: relationship to hypertrophy. Am J Physiol. 1997; 273(3 Pt 2): F348-56.
- 24. RANE MJ, SONG Y, JIN S, BARATI MT, WU R, KAUSAR H, et al. Interplay between Akt and p38 MAPK pathways in the regulation of renal tubular cell apoptosis associated with diabetic nephropathy. Am J Physiol Renal Physiol. 2010; 298(1): F49-61.
- 25. ELMORE S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007; 35(4): 495-516.
- 26. ALBERTS B JA, LEWIS J, et al., editor. Molecular Biology of the Cell. 4th edition ed. New York: Garland Science; 2002.
- 27. KUMAR D, ROBERTSON S, BURNS KD. Evidence of apoptosis in human diabetic kidney. Mol Cell Biochem. 2004; 259(1-2): 67-70.
- 28. HOTCHKISS RS, STRASSER A, McDUNN JE, SWANSON PE. Cell death. N Engl J Med. 2009; 361(16): 1570-83.
- 29. URSEA N, editor. Esentialul in Nefrologie: Fundaţia Română a Rinichiului; 2002.
- 30. BROSIUS FC, COWARD RJ. Podocytes, signaling pathways, and vascular factors in diabetic kidney disease. Adv Chronic Kidney Dis. 2014; 21(3): 304-10.
- 31. CABON L, MARTINEZ-TORRES AC, SUSIN SA. Programmed cell death comes in many flavors. Med Sci (Paris). 2013; 29 (12): 1117-24.
- 32. McLUSKEY K, MOTTRAM JC. Comparative structural analysis of the caspase family with other clan CD cysteine peptidases. Biochem J. 2015; 466(2): 219-32.
- 33. TOWNS R, PIETROPAOLO M, WILEY JW. Stimulation of autophagy by autoantibody-mediated activation of death receptor cascades. Autophagy. 2008; 4(5): 715-6.
- 34. ACEHAN D, JIANG X, MORGAN DG, HEUSER JE, WANG X, AKEY CW. Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol Cell. 2002; 9(2): 423-32.
- 35. DOLEZALOVA D, MRAZ M, BARTA T, PLEVOVA K, VINARSKY V, HOLUBCOVA Z, et al. MicroRNAs regulate p21(Waf1/Cip1) protein expression and the DNA damage response in human embryonic stem cells. Stem Cells. 2012; 30(7): 1362-72.
- 36. LEE HB, YU MR, YANG Y, JIANG Z, HA H. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol. 2003; 14(8 Suppl 3): S241-5.